Breast Cancer

Researchers examine how stem cells promote neuronal growth in tissue regeneration and in cancer progression.

The researchers plan to present updated data at the European Society for Medical Oncology Breast Cancer conference in May.

New information from the IQVIA “Global Medicine Spending and Usage Trends” report highlights the expected growth of specialty pharmacy spending by 2024.

DCIS is a noninvasive condition in which abnormal cells are found in the lining of a breast duct but have not spread to other tissues in the breast.

New research has examined the details surrounding the signaling molecule interleukin-2, which could lead to more targeted therapies for diseases such as cancer.

Guidelines recommend that Ashkenazi Jewish women discuss genetic testing with physicians, but other women with breast cancer are less likely to receive a recommendation of testing.

Research may lead to the development of new types of binding proteins for biological sugar structures, which play a significant role in cancer and infectious diseases.

Patients with a history of cancer have a greater likelihood of developing atrial fibrillation, the most common heart rhythm disorder, compared with the general population.

The new study has found that the lymphedema monitoring technology, marketed by LymphaTech, can effectively detect early arm swelling associated with lymphedema in breast cancer patients.

The growth of the pipeline has led to increases in insurance carriers’ specialty plan spend.

Statins, widely used to lower cholesterol and prevent heart disease, may guard against heart damage caused by certain breast cancer therapies.

“We’re pretty devastated,” said Jessica Harris, a friend of Rutter, in an interview with WFSB. “She beat cancer and lost the battle to coronavirus—it’s just crazy.”

A new study shows that the advantages of digital breast tomosynthesis are maintained over multiple years and rounds of screening compared with digital mammography.

A growth hormone known as insulin-like growth factor-1 has been found to play a role in the development of breast cancer.

AL101 is a potent, selective, injectable small molecule gamma secretase inhibitor and was granted Orphan Drug designation in May 2019 for the treatment of ACC.

Melissa B. Armitage, PharmD, BCOP, a clinical pharmacist who works in breast oncology at the Moffitt Cancer Center in Tampa, Florida, discussed this disease's pathophysiology, natural progression, and risk factors.

Depending on the amount consumed, intake of dairy milk can increase the risk of breast cancer by up to 80%, according to new research from Loma Linda University Health.

In the pivotal phase 3 KEYNOTE-355 study, pembrolizumab (Keytruda, Merck) combined with chemotherapy met one of its dual primary endpoints of progression-free survival (PFS) as a first-line treatment for patients with metastatic triple-negative breast cancer (TNBC) whose tumors expressed programmed death-ligand 1 (PD-L1).

The study was the first to examine proton pump inhibitors use in breast cancer survivors.

Dawn Hershman, MD, MS, offers some potential treatments for aromatase inhibitor-caused arthralgia in breast cancer patients. This video was filmed at the 2019 San Antonio Breast Cancer Symposium.

Because of the vulnerabilities of CDK4/6i-resistant tumors, researchers believe that it is imperative to improve the survival of this group of patients.

Rita Nanda, MD, discusses various immunotherapy drugs in the pipeline and which she thinks will be approved next. This video was filmed December 11 at the 2019 San Antonio Breast Cancer Symposium.

A study suggests that even brief art-making interventions can be beneficial for stressed caregivers of patients with cancer.

Rita Nanda, MD, explains how researchers are aiming to make immunologically silent tumors more inflamed. This video was filmed at the 2019 San Antonio Breast Cancer Symposium.

Although CDK4/6 inhibitors prolong progression-free survival for patients with estrogen receptor-positive breast cancer, the ideal treatment for each patient is currently unclear until adverse effects appear.

The research presented at the 2019 San Antonio Breast Cancer Symposium suggests that the different mechanisms could be exploited to overcome CDK4/6 inhibitor resistance in breast cancer patients.

Check the Pharmacy Times® website for more information and be sure to watch for daily newsletters, online conference articles and videos, and social media updates.

Men with breast cancer had higher mortality than women regardless of cancer type, treatment, and access to care.

Specialty Pharmacy Times will be on-site in San Antonio, TX, for the 2019 San Antonio Breast Cancer Symposium, taking place December 10 to 14, 2019.

Trastuzumab-dkst (Ogivri, Mylan, Biocon), a biosimilar to trastuzumab (Herceptin, Genentech Inc.), has been launched in the US, according to an announcement from Mylan N.V. and Biocon Ltd. It is the first biosimilar approved by the FDA and recommended by the FDA Oncologic Drugs Advisory Committee.